Correlation between Demographic Characteristic and Oxidized Low Density Lipoprotein (OxLDL-IgM and OxLDL-IgG) Antibodies levels in patients with Systemic Lupus Erythematosus Patients

Nusaibah K.  Al-Zubaidi; Suha A.  Al-Fakhar; Mohammad H.  Al-Osami

doi:10.32007/jfacmedbagdad.6612002

Authors

Nusaibah K. Al-Zubaidi Department of Medical Microbiology, College of Medicine, University of Baghdad, Baghdad, Iraq https://orcid.org/0009-0002-5926-6463
Suha A. Al-Fakhar Clinical Communicable Disease Research Unit, College of Medicine, University of Baghdad, Baghdad, Iraq https://orcid.org/0000-0001-7964-7912
Mohammad H. Al-Osami Department of Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq. https://orcid.org/0000-0001-8521-5876

DOI:

https://doi.org/10.32007/jfacmedbagdad.6612002

Keywords:

Immunoglobulins G; , Immunoglobulins M; , Oxidized Low-Density Lipoprotein antibody; , Obesity;, Systemic Lupus Erythematosus.

Abstract

Background: Systemic Lupus Erythematosus (SLE) may affect one or more organ systems; as time goes on, other manifestations may start to appear. Musculoskeletal, cutaneous, renal, and endocrine systems are all involved in SLE. The nervous system, hematological, vascular, pulmonary, gastrointestinal, and ocular imbalance of the immune response and the production of autoantibodies such as anti-oxidized Low-Density Lipoprotein LDL antibodies have a clear impact on the body’s organs and the development of complications of the disease.

Objectives: To assess the levels of anti-oxLDL (IgM-Abs) and anti-oxLDL (IgG-Abs) as biomarkers for disease activity in SLE patients and their relationship to demographic characteristics.

Patients and Methods: The study comprised 100 of SLE patients admitted to the Rheumatology Unit at Baghdad Teaching Hospital, age range (33.4 to 9.95) years, including 7 males and 93 females. An enzyme-linked immunosorbent Assay ELISA was used to measure the levels of serum oxLDL (IgM-Abs) and oxLDL (IgG-Abs).

Results: The results of the present study showed that there was a significant difference between the levels of anti-oxLDL IgM antibodies(Abs) in SLE patients in obese and non-obese groups since the levels of anti-oxLDL-IgM Abs in obese patients were (3.14 µg/L) and non-obese patients were (5.13 µg/L) (P=0.005), while in SLE patients with Diabetes Mellitus (D.M.), the levels of anti-ox LDL-IgM Abs were (3.80 µg/L) and in SLE patients with no DM were (5.13 µg/L). Also, the results showed that there were no significant differences between levels of anti-oxLDL IgG Abs in obese patients with SLE (6.28 µg/L) and non-obese patients with SLE (10.25µg/L) P > 0.05.

Conclusion: There was found a significant difference between levels of anti-oxLDL IgM Abs in obese and non-obese in patients with SLE, and no significant differences between the levels of anti-oxLDL IgG Abs in the same groups of patients.

Downloads

Download data is not yet available.

Author Biographies

Nusaibah K. Al-Zubaidi, Department of Medical Microbiology, College of Medicine, University of Baghdad, Baghdad, Iraq

Department of Medical Microbiology, College of Medicine, University of Baghdad, Baghdad, Iraq
Suha A. Al-Fakhar , Clinical Communicable Disease Research Unit, College of Medicine, University of Baghdad, Baghdad, Iraq

Clinical Communicable Disease Research Unit, College of Medicine, University of Baghdad, Baghdad, Iraq
Mohammad H. Al-Osami, Department of Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq.

Department of Medicine, College of Medicine, University of Baghdad

References

Gustafsson, JT. and Svenungsson E. Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus, Autoimmunity, 2014;47(2), pp 67-76.

https://doi.org/10.3109/08916934.2013.856005

Danchenko N, Satia JA, Anthony MS.. 'Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden', Lupus,2006;15(5) pp 308-18.

https://doi.org/10.1191/0961203306lu2305xx

Perricone C, Versini M, Ben-Ami D, Gertel S, Watad A, Segel MJ, et al. 'Smoke, and autoimmunity: The fire behind the disease', Autoimmunity Reviews,2016;15(4), pp 354-74.

https://doi.org/10.1016/j.autrev.2016.01.001

Arnson Y, Shoenfeld Y, Amital H. 'Effects of tobacco smoke on immunity, inflammation, and autoimmunity', Journal of Autoimmunity,2010;34(3), pp J258-J265.

https://doi.org/10.1016/j.jaut.2009.12.003

Tektonidou MG, Kravvariti E, Konstantonis G, Tentolouris N, Sfikakis PP, Protogerou A. 'Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid Arthritis', Autoimmunity Reviews,2017;16(3), pp 308-12.

https://doi.org/10.1016/j.autrev.2017.01.009

Sara K Tedeschi, Medha Barbhaiya, Susan Malspeis, Bing Lu, Jeffrey A Sparks, Elizabeth W Karlson, Walter Willett, Karen H Costenbader. 'Obesity and the risk of systemic lupus erythematosus among women in the Nurses Health Studies', Seminars in Arthritis and Rheumatism,2017;47(3), pp 376-383.

https://doi.org/10.1016/j.semarthrit.2017.05.011

Chambers, S. A., et al. 'Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality', Ann Rheum Dis,2007;66(9), pp 1173-1177, https://doi.org/10.1136/ard.2006.062984

Li, H., Li, D.-q., Li, X.-x., & Wang, L.-q. 'The association between oxidized low-density lipoprotein antibodies and hematological diseases', Lipids in health and disease,20161;5(1), pp 1-10.

Esdaile, J. M., M. Abrahamowicz, T. Grodzicky, et al.. 'Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus', Arthritis Rheum.,2001;44(10), PP(2331-2337. https://doi.org/10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I

Manzi, S., E. N. Meilahn, J. E. Rairie, et al. 'Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study', Am. J. Epidemiol.1997;145(5), pp 408-415.

https://doi.org/10.1093/oxfordjournals.aje.a009122

Pons-Estel, G. J., L. A. Gonzalez, J. Zhang, et al. 'Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort', Rheumatology (Oxford),2009;48, pp 817-822.

https://doi.org/10.1093/rheumatology/kep102

Jennifer L. Rodgers, Jarrod Jones, Samuel I. Bolleddu, Sahit Vanthenapalli, Lydia E. Rodgers, Kinjal Shah, Krishna Karia, and Siva K. Panguluri. Cardiovascular Risks Associated with Gender and Aging, J Cardiovasc Dev Dis. 2019 Jun; https://doi.org/10.3390/jcdd6020019

Golder, V., & Tsang-A-Sjoe, M. W. (2020). Treatment targets in SLE: remission and low disease activity state, Rheumatology,2020;59(Supplement_5), pp v19-v28.

https://doi.org/10.1093/rheumatology/keaa420

Eng M. Tan, Alan S. Cohe, James F. Fries, Alfonse T. Masi, Dennis J. Mcshane, Naomi F. Rothfield, Jane Green Schaller, Norman Talal, and Robert J. Winchester. 'The 1982 revised criteria for the classification of systemic lupus erythematosus'. Arthritis & Rheumatism,1982 ;25(11), pp 1271-1277. Available at: https://doi.org/10.1002/art.1780251101

Michelle Petri. 'Infection In Systemic Lupus Erythematosus', Journal of Rheumatic Disease Clinics of North America,1998;24(2), pp 423-456. Available at: https://doi.org/10.1016/S0889-857X(05)70016-8.

https://doi.org/10.1016/S0889-857X(05)70016-8

Petri, M., S. Perez-Gutthann, D. Spence, and M. C. Hochberg. Risk factors for coronary artery disease in patients with systemic lupus erythematosus, The American Journal of Medicine,1992;93(5), pp 513-519.

https://doi.org/10.1016/0002-9343(92)90578-Y

Nived, O., Ingvarsson, R. F., Jöud, A., Linge, P., Tydén, H., Jönsen, A., & Bengtsson, A. A. (2020). Disease duration, age at diagnosis, and organ damage are important factors for cardiovascular disease in SLE. Lupus Science & Medicine,2020 ;(1), e000398.

https://doi.org/10.1136/lupus-2020-000398

Munguia-Realpozo, P., et al. Systemic lupus erythematosus and hypertension. Autoimmunity Reviews,2019;18(10), 102371.

https://doi.org/10.1016/j.autrev.2019.102371

Patterson, S. L., Schmajuk, G., Jafri, K., Yazdany, J., & Katz, P. Obesity is independently associated with worse patient‐reported outcomes in women with systemic lupus erythematosus. Arthritis care & research,2019;71(1), 126-133.

https://doi.org/10.1002/acr.23576

Rizk, A., Gheita, T. A., Nassef, S., & Abdallah, A. The impact of obesity in systemic lupus erythematosus on disease parameters, quality of life, functional capacity, and the risk of atherosclerosis. International journal of rheumatic diseases,2012;15(3), 261-6267.

https://doi.org/10.1111/j.1756-185X.2011.01698.x

Segura, B. T., Bernstein, B. S., McDonnell, T., Wincup, C., M Ripoll, V., Giles, I., . . . Rahman, A. Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. Rheumatology,2020;59(3), 524-533.

https://doi.org/10.1093/rheumatology/kez516

Angelica Sinicato, N., Aparecida da Silva Cardoso, P., & Appenzeller, S. Risk factors in cardiovascular disease in systemic lupus erythematosus. Current Cardiology Reviews,2013;9(1), 15-19.

https://doi.org/10.2174/157340313805076304

Masztalewicz, M., Nowacki, ]P., Kotlęga, D., Bajer-Czajkowska, A., & Drechsler, H. Anti-oxLDL antibodies are clinically insignificant for stroke patients. Neurological Research,2014;36(1), 86-91.

https://doi.org/10.1179/1743132813Y.0000000268

Omar, N. N., Hefnawy, M. H. E., Mohamed, F., Heider, N. M., & Hamed, H. I. Assessment of oxLDL, anti-oxLDL antibodies and lipoprotein-associated phospholipa]se A2 as cardiovascular risk markers in obese adolescents with and without T1DM. Bulletin of Faculty of Pharmacy, Cairo University,2017;55(2), 325-331.

https://doi.org/10.1016/j.bfopcu.2017.05.002

Van den Berg, V. J., Vroegindewey, M. M., Kardys, I., Boersma, E., Haskard, D., Hartley, A., & Khamis, R. Anti-oxidized LDL antibodies and coronary artery disease: a systematic review. Antioxidants,2019;8(10), 484, doi: 10.3390/antiox8100484.

https://doi.org/10.3390/antiox8100484

Shiri-Sverdlov, R., Dos Reis, I. M., Oligschlaeger, Y., Hendrikx, T., Meesters, D. M., Vanclooster, A.,&… Houben, T. . The influence of a conjugated pneumococcal vaccination on plasma antibody levels against oxidized low-density lipoprotein] in metabolic disease patients: a single-arm pilot clinical trial. Antioxidants,2021 ;10(61), 129.

https://doi.org/10.3390/antiox10010129

Alouffi, S., Faisal, M., Alatar, A. A., & Ahmad, S. . Oxidative modification of LDL by various physicochemical techniques: its probable role in diabetes coupled with CVDs. BioMed Research International,2018.

https://doi.org/10.1155/2018/7390612

Maria F Lopes-Virella 1, Gabriel Virella, Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis, Atheroscler Thromb,. 2013;20(10):743-54.

https://doi.org/10.5551/jat.19281